Scientists track rare immune disease to unlock its secrets
NCT ID NCT00001350
First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 5 times
Summary
This study follows people with autoimmune lymphoproliferative syndrome (ALPS) and their relatives over many years. Researchers will collect blood and tissue samples, track symptoms, and study genetics to better understand why the immune system attacks the body. The goal is to learn how the disease develops and find better ways to manage it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could lead to a better understanding of ALPS and point toward targeted treatments for this rare immune disorder.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take many years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.